Baseline α-synuclein seeding activity and disease progression in sporadic and genetic Parkinson's disease in the PPMI cohort
Open Access
- 6 August 2025
- journal article
- Published by Elsevier in EBioMedicine
- Vol. 119, 105866
Abstract
No abstract availableKeywords
Funding Information
- Aligning Science Across Parkinson's
- Michael J. Fox Foundation for Parkinson's Research
- National Institute of Neurological Disorders and Stroke
This publication has 35 references indexed in Scilit:
- Investigating alpha‐synuclein co‐pathology in Alzheimer's disease by means of cerebrospinal fluid alpha‐synuclein seed amplification assayAlzheimer's & Dementia, 2024
- A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson’s Disease in Participants With Leucine‐Rich Repeat Kinase 2 MutationClinical Pharmacology & Therapeutics, 2021
- A rapid α‐synuclein seed assay of Parkinson’s disease CSF panel shows high diagnostic accuracyAnnals of Clinical and Translational Neurology, 2020
- Development of a Disease Progression Model for Leucine‐Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial DesignsClinical Pharmacology & Therapeutics, 2019
- The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohortAnnals of Clinical and Translational Neurology, 2018
- Progression in the LRRK2-Associated Parkinson Disease PopulationJAMA Neurology, 2018
- Association ofGBAMutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson DiseaseJAMA Neurology, 2016
- Clinical Correlations With Lewy Body Pathology inLRRK2-Related Parkinson DiseaseJAMA Neurology, 2015
- Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunctionActa Neuropathologica, 2009
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing resultsMovement Disorders, 2008